UNSPSC 51412013: Imolamine hydrochloride

This classification denotes a vasodilating agent C14H20N4O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YJ3KV70R41, chemically known as .delta.2-1,2,4-oxadiazoline, 4-(2-(diethylamino)ethyl)-5-imino-3-phenyl-, monohydrochloride, but more generally known as imolamine hydrochloride, which bears US NIH Compound Identifier 27500. Most nations, for tariff and trade purposes, schedule imolamine hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, IMOLAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

SMILES: CCN(CC)CCN1C(NOC1=N)C2CCCCC2.CL.

UNSPSC 51412013 Imolamine hydrochloride is a Commodity code covering specific pharmaceutical active ingredients and finished-form medications used in emergency medical care, hospital pharmacy, and public health programs. State and local governments buy these products primarily for emergency medical services, firefighting agencies, and state health and human services programs. The scope includes both individual medication line items (vials, injections, formulations in specified strengths and volumes) and bulk pharmaceutical sourcing through cooperative purchasing arrangements. Issuing bodies include city fire departments, state health commissions, and multistate cooperative purchasing alliances that aggregate demand across participating state and local agencies. Most recent solicitations show demand driven by emergency medical services and state pharmacy benefit programs rather than retail distribution.

Activity is concentrated in Florida and Minnesota with additional participation from Texas and Oregon through cooperative purchasing vehicles. The City of Tampa's Fire Rescue department issued IFB 26P00188 in April 2026 for advanced life support medications including epinephrine, diltiazem, and adenosine with a $40,000 estimated contract value and a response deadline of April 8, 2026, using a small local business enterprise sheltered market with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 due March 26, 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across state and local government facilities in Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers and carry a 3 percent administrative fee on all contract purchases. The Texas Health and Human Services Commission posted RFI HHS0017013 in March 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs as preliminary market research before a formal procurement.